Literature DB >> 21179528

Monoclonal antibodies in multiple sclerosis treatment: current and future steps.

Claire L Helliwell1, Alasdair J Coles.   

Abstract

Year:  2009        PMID： 21179528      PMCID： PMC3002635          DOI： 10.1177/1756285609337827

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN： 1756-2856            Impact factor:   6.570


× No keyword cloud information.
  36 in total

1.  "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28.

Authors:  Philip Tan; David A Mitchell; Timothy N Buss; Margaret A Holmes; Claudio Anasetti; Jefferson Foote
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

2.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

Authors:  Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

3.  Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Authors:  Bibiana Bielekova; Marta Catalfamo; Susan Reichert-Scrivner; Amy Packer; Magdalena Cerna; Thomas A Waldmann; Henry McFarland; Pierre A Henkart; Roland Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

4.  New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab.

Authors:  Hans-Peter Hartung
Journal:  Lancet Neurol       Date:  2009-01       Impact factor: 44.182

5.  Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17.

Authors:  Sudeepta Aggarwal; Nico Ghilardi; Ming-Hong Xie; Frederic J de Sauvage; Austin L Gurney
Journal:  J Biol Chem       Date:  2002-11-03       Impact factor: 5.157

6.  Onset of multiple sclerosis associated with anti-TNF therapy.

Authors:  N L Sicotte; R R Voskuhl
Journal:  Neurology       Date:  2001-11-27       Impact factor: 9.910

7.  Treatment with chimeric anti-human CD40 antibody suppresses MRI-detectable inflammation and enlargement of pre-existing brain lesions in common marmosets affected by MOG-induced EAE.

Authors:  Bert A 't Hart; Erwin L A Blezer; Herbert P M Brok; Louis Boon; Mark de Boer; Jan Bauer; Jon D Laman
Journal:  J Neuroimmunol       Date:  2005-04-09       Impact factor: 3.478

8.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Authors:  Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

9.  Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.

Authors:  Bibiana Bielekova; Nancy Richert; Thomas Howard; Gregg Blevins; Silva Markovic-Plese; Jennifer McCartin; Joseph A Frank; Jens Würfel; Joan Ohayon; Thomas A Waldmann; Henry F McFarland; Roland Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-25       Impact factor: 11.205

10.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245
View more
  7 in total

Review 1.  Disease-Modifying Treatment in Progressive Multiple Sclerosis.

Authors:  John Robert Ciotti; Anne Haney Cross
Journal:  Curr Treat Options Neurol       Date:  2018-04-07       Impact factor: 3.598

Review 2.  Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?

Authors:  Shani Witman Tsur; Eli Adrian Zaher; Meydan Tsur; Karolina Kania; Alicja Kalinowska-Łyszczarz
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

3.  Effects of antibody disulfide bond reduction on purification process performance and final drug substance stability.

Authors:  Wai Keen Chung; Brian Russell; Yanhong Yang; Michael Handlogten; Suzanne Hudak; Mingyan Cao; Jihong Wang; David Robbins; Sanjeev Ahuja; Min Zhu
Journal:  Biotechnol Bioeng       Date:  2017-03-06       Impact factor: 4.530

4.  Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis.

Authors:  Fernando Cavalcanti; Elena Gonzalez-Rey; Mario Delgado; Clara P Falo; Leyre Mestre; Carmen Guaza; Francisco O'Valle; Michele M P Lufino; Jordi Xaus; Cristina Mascaró; Serena Lunardi; Natalia Sacilotto; Paola Dessanti; David Rotllant; Xavier Navarro; Mireia Herrando-Grabulosa; Carlos Buesa; Tamara Maes
Journal:  Pharmaceutics       Date:  2022-07-06       Impact factor: 6.525

5.  A mushroom extract Piwep from Phellinus igniarius ameliorates experimental autoimmune encephalomyelitis by inhibiting immune cell infiltration in the spinal cord.

Authors:  Lan Li; Guang Wu; Bo Young Choi; Bong Geom Jang; Jin Hee Kim; Gi Ho Sung; Jae Youl Cho; Sang Won Suh; Hyoung Jin Park
Journal:  Biomed Res Int       Date:  2014-01-27       Impact factor: 3.411

6.  Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.

Authors:  Z Li; S Richards; H K Surks; A Jacobs; M A Panzara
Journal:  Clin Exp Immunol       Date:  2018-10-01       Impact factor: 4.330

7.  Anti-CD20 treatment effectively attenuates cortical pathology in a rat model of widespread cortical demyelination.

Authors:  Michaela T Haindl; Muammer Üçal; Benjamin Klaus; Lennart Tögl; Jana Dohrmann; Milena Z Adzemovic; Christian Enzinger; Sonja Hochmeister
Journal:  J Neuroinflammation       Date:  2021-06-15       Impact factor: 8.322
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.